| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP3A43 |
| Uniprot No | Q9HB55 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-393aa |
| 氨基酸序列 | MDLIPNFAMETWVLVATSLVLLYIYGTHSHKLFKKLGIPGPTPLPFLGTILFYLRRSLNKIPSWAWWLTPVIPALWEAEAGGSPKVRSSRPALPTWVFGILTENVMKNTEKCGALFPFLTPVFEALNIGLFPKDVTHFLKNSIERMKESRLKDKQKHRVDFFQQMIDSQNSKETKSHKALSDLELVAQSIIIIFAAYDTTSTTLPFIMYELATHPDVQQKLQEEIDAVLPNKAPVTYDALVQMEYLDMVVNETLRLFPVVSRVTRVCKKDIEINGVFIPKGLAVMVPIYALHHDPKYWTEPEKFCPERFSKKNKDSIDLYRYIPFGAGPRNCIGMRFALTNIKLAVIRALQNFSFKPCKETQIPLKLDNLPILQPEKPIVLKVHLRDGITSGP |
| 预测分子量 | 52.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYP3A43重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**：*"cDNA Cloning and Initial Characterization of CYP3A43. a Novel Human Cytochrome P450"*
**作者**：Domanski TL, et al.
**摘要**：该研究首次克隆并表达了CYP3A43的重组蛋白，发现其在体外对典型CYP3A底物(如睾酮)的代谢活性显著低于CYP3A4.提示其在药物代谢中的作用有限，但可能具有组织特异性功能。
2. **文献名称**：*"Differential Regulation of CYP3A4 and CYP3A43: Evidence for a Unique Promoter Structure"*
**作者**：Westlind-Johnsson A, et al.
**摘要**：通过对比CYP3A43与CYP3A4的启动子区域，发现两者转录调控机制存在差异。重组CYP3A43蛋白的表达水平受特定核受体(如PXR)调控较弱，可能解释其低丰度表达。
3. **文献名称**：*"Genetic Polymorphisms and Expression of CYP3A43 in Human Tissues"*
**作者**：Krausz KW, et al.
**摘要**：研究鉴定了CYP3A43基因的多个单核苷酸多态性(SNPs)，并利用重组蛋白技术分析其对酶活性的影响。结果显示部分SNPs导致蛋白稳定性下降，可能影响个体化用药。
---
**注**：以上文献为示例性质，实际引用需核对原始论文。若需近期研究，建议检索PubMed等数据库(关键词：CYP3A43 + recombinant expression)。
CYP3A43 is a member of the cytochrome P450 (CYP) superfamily, specifically belonging to the CYP3A subfamily, which plays a critical role in the oxidative metabolism of endogenous compounds and xenobiotics, including drugs, toxins, and steroids. Unlike its well-studied isoforms CYP3A4 and CYP3A5. CYP3A43 exhibits lower enzymatic activity and is expressed at relatively low levels in humans, primarily in the liver, brain, gastrointestinal tract, and reproductive tissues. Its exact physiological role remains unclear, though it is hypothesized to participate in steroid hormone metabolism and contribute to interindividual variability in drug responses.
Recombinant CYP3A43 protein is engineered using heterologous expression systems (e.g., bacterial, yeast, or mammalian cells) to overcome its low natural abundance and enable functional characterization. This recombinant protein allows researchers to study its substrate specificity, catalytic activity, and interactions with drugs or inhibitors. Studies suggest CYP3A43 has a narrower substrate range compared to CYP3A4. with weak activity toward typical CYP3A substrates like testosterone or midazolam. Structural analyses reveal unique amino acid residues in its substrate-binding pockets, potentially explaining its distinct catalytic properties.
Research on recombinant CYP3A43 is vital for understanding its role in drug metabolism, particularly in scenarios where its expression is upregulated or genetically polymorphic. Variations in the CYP3A43 gene may influence enzyme function, contributing to personalized differences in drug efficacy or toxicity. Additionally, its expression in extrahepatic tissues hints at localized roles in hormone regulation or neurosteroid metabolism. Despite progress, further studies are needed to clarify its endogenous substrates, regulatory mechanisms, and relevance to disease pathways, such as cancer or neuroendocrine disorders. Recombinant protein tools remain essential for unraveling these complexities.
×
